{"product_id":"dominant-negative-tgf-beta-receptor-type-ii-tgf-beta-rii-lentivirus-bhv18200011","title":"Dominant Negative TGF-β Receptor Type II (TGF-βRII) Lentivirus","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-license-box{background:#f5f5f5;border:1px solid #ddd;border-radius:4px;padding:12px 16px;font-size:14px;color:#444}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n\u003ch2\u003eScientific Background\u003c\/h2\u003e\n\u003cp\u003eTransforming growth factor receptor beta 2 (TGFBR2), or TGFβRII, encodes the TGFβ receptor serine\/threonine kinase, which is a transmembrane protein that forms a heterodimeric complex with other receptor proteins and binds TGFβ. The association of TGFβ with TGFβRII leads to the phosphorylation of proteins, such as SMADs, involved in cell proliferation, cell cycle arrest, wound healing, and immunosuppression. Dysfunction of the TFGβ signaling tends to result in cancer development and progression. In the case of solid tumors, TGFβ signaling plays a role in creating a highly immunosuppressive TME (tumor microenvironment), restricting the efficacy of CAR (chimeric receptor antigen)- T cells, which have proved successful in the treatment of hematological cancers. Recently, the use of CAR-T cells armored with a dominant negative form of TGFβRII, missing the intracellular kinase domain, for the treatment of prostate cancer resulted in promising outcomes. 5 out of 13 patients did suffer cytokine release syndrome, which continues to be a concern with CAR-T applications, but on the whole the use of a dominant negative TGFβ receptor to armor CAR-T cells appears to be an approach that deserves further attention in the cancer therapy field.\u003c\/p\u003e\n\u003ch2\u003eProduct Description\u003c\/h2\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eHIV-based · VSV-G-pseudotyped · SIN=Yes\u003c\/span\u003e\u003cp\u003eDominant Negative TGF-β Receptor Type II (TGF-βRII) Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles ready to transduce nearly all types of mammalian cells, including primary and non-dividing cells. These viruses result in expression of human dominant negative TGF-βRII, missing the intracellular kinase domain (NM_003242.6; amino acid 1-191), driven by an EF1a promoter and a puromycin selection marker.\u003c\/p\u003e\n\u003ch2\u003eTechnical Details\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eVector Type\u003c\/th\u003e\n\u003ctd\u003eHIV-based, VSV-G-pseudotyped lentiviral vector\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePayload \/ Construct\u003c\/th\u003e\n\u003ctd\u003eDominant Negative TGF-βRII\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget Antigen \/ Gene\u003c\/th\u003e\n\u003ctd\u003eTGF-βRII (Dominant Negative) (TGFBR2 DN)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSignaling \/ Architecture\u003c\/th\u003e\n\u003ctd\u003eN\/A (transgene expression)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSelection Marker\u003c\/th\u003e\n\u003ctd\u003ePuromycin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReporter\u003c\/th\u003e\n\u003ctd\u003eNone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eBiosafety Level\u003c\/th\u003e\n\u003ctd\u003eBSL-2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSIN Vector\u003c\/th\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eThe lentivirus particles were produced in HEK293T cells in medium containing 90% DMEM + 10% FBS.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSupplied As\u003c\/th\u003e\n\u003ctd\u003eTwo vials (500 µl x 2) of lentivirus at a titer ≥10\u003csup\u003e7\u003c\/sup\u003e TU\/ml. The titer will vary with each lot; the exact value is provided with each shipment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e−80°C; avoid repeated freeze-thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHazardous Shipping\u003c\/th\u003e\n\u003ctd\u003eUN3373\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eApplications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eExpression of human dominant negative TGF-βRII in cells of interest.\u003c\/li\u003e\n\u003cli\u003eGenerate cell pools or stable cell lines expressing human TGF-βRII following puromycin selection.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eBiosafety \u0026amp; Safety\u003c\/h2\u003e\n\u003cp\u003eTo generate a dominant negative TGF-βRII expressing stable cell line, remove the growth medium 48 hours after transduction and replace it with fresh growth medium containing the appropriate amount of puromycin (as pre-determined from a killing curve, bpsbioscience.com\/cell-line-faq), for antibiotic selection of transduced cells, followed by clonal selection.  The lentiviruses are produced with a SIN (self-inactivation) lentivector which ensures self-inactivation of the lentiviral construct after transduction and after integration into the genomic DNA of the target cells. None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal and are not present in the lentivirus particle. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS Bioscience recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions. Troubleshooting Guide: Visit bpsbioscience.com\/lentivirus-faq for detailed troubleshooting instructions. For further questions, please email support@bpsbioscience.com.\u003c\/p\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cstrong\u003e⚠ Safety Note:\u003c\/strong\u003e Avoid freeze\/thaw cycles.\u003c\/div\u003e\n\u003c\/div\u003e","brand":"BPS Bioscience","offers":[{"title":"500 uL x 2","offer_id":53322953032045,"sku":"78928","price":1315.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/78928-1.png?v=1778643138","url":"https:\/\/www.ebiohippo.com\/products\/dominant-negative-tgf-beta-receptor-type-ii-tgf-beta-rii-lentivirus-bhv18200011","provider":"BioHippo","version":"1.0","type":"link"}